ArticleDiagnostic microbiology and infectious disease2012
Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility.
Article in Diagnostic microbiology and infectious disease, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cryptococcosis-a systematic review to inform the World Health Organization Fungal Priority Pathogens List.Medical mycology · 2024Pooled it
- Cryptococcosis in Colombia: Analysis of Data from Laboratory-Based Surveillance 2017-2024.Journal of fungi (Basel, Switzerland) · 2026Article
- Development of a Multiplex qPCR to Detect and IdentifyACS omega · 2025Article
- Review
- Optimizing antifungal dosing for invasiveFrontiers in pharmacology · 2025Article
- Article
- Pulmonary Cryptococcosis.Journal of fungi (Basel, Switzerland) · 2022Review
- Treatment recommendations for non-HIV associated cryptococcal meningoencephalitis including management of post-infectious inflammatory response syndrome.Frontiers in neurology · 2022Review
- Antifungal susceptibility of clinical Cryptococcus gattii isolates from Colombia varies among molecular types.Medical mycology · 2021Article
- Review
- Molecular epidemiology and antifungal susceptibilities of Cryptococcus species isolates from HIV and non-HIV patients in Southwest China.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Article
- Article
- Clinical and microbiological characteristics of Cryptococcus gattii isolated from 7 hospitals in China.BMC microbiology · 2020Article
- Article
- Corticosteroids for Posttransplant Immune Reconstitution Syndrome inOpen forum infectious diseases · 2019Article
- Central Nervous System Cryptococcal Infections in Non-HIV Infected Patients.Journal of fungi (Basel, Switzerland) · 2019Review
- Macrolides Inhibit Capsule Formation of Highly VirulentAntimicrobial agents and chemotherapy · 2019Article
- Genotypic diversity and clinical outcome of cryptococcosis in renal transplant recipients in Brazil.Emerging microbes & infections · 2019Article
- Cryptococcus gattii Complex Infections in HIV-Infected Patients, Southeastern United States.Emerging infectious diseases · 2018Article
- Ecoepidemiology of Cryptococcus gattii in Developing Countries.Journal of fungi (Basel, Switzerland) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cryptococcus gattii causes infection in tropical and subtropical regions worldwide but has garnered increased attention since its 1999 emergence in North America. C. gattii can be divided into 4 molecular types that may represent cryptic species. Recent evidence has shown that azole antifungal MIC values differ among these molecular types. We tested a large collection of C. gattii isolates for susceptibility to 4 azole drugs. We found that isolates of molecular type VGII have the highest geometric mean (GM) fluconazole MIC values (8.6 μg/mL), while isolates of molecular type VGI have the lowest (1.7 μg/mL). For fluconazole, itraconazole, and voriconazole GM MIC values, VGI < VGIII < VGIV < VGII. The GM MIC values for posaconazole were similarly represented across molecular types, with the exception that VGII < VGIII and VGIV. We used the MIC values to establish preliminary epidemiologic cutoff values for each azole and molecular type of C. gattii.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.